Guolo F, et al. Blood Cancer J. 2020: Treatment with Vyxeos Liposomal in a compassionate use program

Back to resources

Discover the full outcomes of this multicentre cohort in Italy, where 71 patients were treated with Vyxeos Liposomal showing a 12-month OS of 68.6% and a manageable adverse events profile.1

Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Safety Vyxeos Liposomal Data

DOWNLOAD HERE
REFERENCES:
  1. Guolo F, et al. Blood Cancer J 2020;10.1038/s41408-020-00361-8

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100175 | September 2021